Target Information
General Information of This Target (ID: PATR0EDEOA)
| Target Name | Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) |
|||||
|---|---|---|---|---|---|---|
| Gene Name | GSPT1; ERF3A |
|||||
| Gene ID | ||||||
| Synonym | ERF3A |
|||||
| Sequence |
MELSEPIVENGETEMSPEESWEHKEEISEAEPGGGSLGDGRPPEESAHEMMEEEEEIPKP
KSVVAPPGAPKKEHVNVVFIGHVDAGKSTIGGQIMYLTGMVDKRTLEKYEREAKEKNRET WYLSWALDTNQEERDKGKTVEVGRAYFETEKKHFTILDAPGHKSFVPNMIGGASQADLAV LVISARKGEFETGFEKGGQTREHAMLAKTAGVKHLIVLINKMDDPTVNWSNERYEECKEK LVPFLKKVGFNPKKDIHFMPCSGLTGANLKEQSDFCPWYIGLPFIPYLDNLPNFNRSVDG PIRLPIVDKYKDMGTVVLGKLESGSICKGQQLVMMPNKHNVEVLGILSDDVETDTVAPGE NLKIRLKGIEEEEILPGFILCDPNNLCHSGRTFDAQIVIIEHKSIICPGYNAVLHIHTCI EEVEITALICLVDKKSGEKSKTRPRFVKQDQVCIARLRTAGTICLETFKDFPQMGRFTLR DEGKTIAIGKVLKLVPEKD Click to Show/Hide
|
|||||
| Family | TRAFAC class translation factor GTPase superfamily, Classic translation factor GTPase family, ERF3 subfamily |
|||||
| Uniprot Entry | ||||||
| HGNC ID | ||||||
| KEGG ID | ||||||
Full List of The ADC Related to This Target
Investigative
| ADC Name | Antibody | Antigen | Payload | Linker | ADC Info |
|---|---|---|---|---|---|
|
IGAC-3
[1]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
MP-Ala-Ala-PAB |
|
|
IGAC-4
[1]
|
Undisclosed |
Undisclosed |
Smol006 |
MP-Ala-Ala-PAB |
|
|
IGAC-7
[1]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
MP-Ala-Ala-PAB |
|
|
IGAC-8
[1]
|
Undisclosed |
Undisclosed |
Smol006 |
MP-Ala-Ala-PAB |
|
|
IGAC-25
[1]
|
pinatuzumab |
Insulin-like growth factor 1 receptor (IGF1R) |
Smol006 |
MP-Ala-Ala-PAB |
|
|
IGAC-26
[1]
|
gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
Smol006 |
MP-Ala-Ala-PAB |
|
|
IGAC-31
[1]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
IG-L-14 linker |
|
|
IGAC-34
[1]
|
pinatuzumab |
Insulin-like growth factor 1 receptor (IGF1R) |
Smol006 |
IG-L-14 linker |
|
|
IGAC-39
[1]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
MP-Ala-Ala-PAB |
|
|
IGAC-57
[1]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
IG-L-16 linker |
|
|
IGAC-58
[1]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
IG-L-63 linker |
|
|
IGAC-59
[1]
|
pinatuzumab |
Insulin-like growth factor 1 receptor (IGF1R) |
Smol006 |
IG-L-63 linker |
|
|
IGAC-65
[1]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
IG-L-65 linker |
|
|
IGAC-66
[1]
|
pinatuzumab |
Insulin-like growth factor 1 receptor (IGF1R) |
Smol006 |
IG-L-65 linker |
|
|
IGAC-69
[1]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
IG-L-68 linker |
|
|
IGAC-70
[1]
|
pinatuzumab |
Insulin-like growth factor 1 receptor (IGF1R) |
Smol006 |
IG-L-68 linker |
|
|
IGAC-97
[1]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
IG-L-74 linker |
|
|
WO2024169913A1 ADC01-01-8
[2]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC01-01-4
[2]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC01-02-8
[2]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC01-02-4
[2]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC01-06-8
[2]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC01-06-4
[2]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B63 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC01-07-4
[2]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B63 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC01-08-8
[2]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
(Linker-02)MC-PEG-VA-PAB |
|
|
WO2024169913A1 ADC01-08-4
[2]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
(Linker-03)SMCC-TAZ-PEG-VC-PAB |
|
|
WO2024169913A1 ADC03-01-8
[2]
|
SYM003 (anti-Claudin 18.2) |
Claudin-18.2 (CLDN18.2) |
B19 |
(Linker-03)SMCC-TAZ-PEG-VC-PAB |
|
|
WO2024169913A1 ADC03-01-4
[2]
|
SYM003 (anti-Claudin 18.2) |
Claudin-18.2 (CLDN18.2) |
B19 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC04-01-8
[2]
|
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC04-02-8
[2]
|
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC04-06-8
[2]
|
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC04-06-4
[2]
|
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B63 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC04-07-8
[2]
|
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B63 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC04-07-4
[2]
|
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
(Linker-02)MC-PEG-VA-PAB |
|
|
WO2024169913A1 ADC04-08-8
[2]
|
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
(Linker-02)MC-PEG-VA-PAB |
|
|
WO2024169913A1 ADC04-08-4
[2]
|
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
(Linker-03)SMCC-TAZ-PEG-VC-PAB |
|
|
WO2024169913A1 ADC04-09-8
[2]
|
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
Smol006 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC04-09-4
[2]
|
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
Smol006 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC07-01-8
[2]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC07-01-4
[2]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC07-02-8
[2]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC07-02-4
[2]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC07-06-8
[2]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B63 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC07-06-4
[2]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B63 |
Mc-Val-Ala-PABC |
|
|
WO2024169913A1 ADC07-08-8
[2]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
(Linker-03)SMCC-TAZ-PEG-VC-PAB |
|
|
WO2024169913A1 ADC07-08-4
[2]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
(Linker-03)SMCC-TAZ-PEG-VC-PAB |
|
|
WO2024169913A1 ADC07-09-8
[2]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC07-09-4
[2]
|
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
Smol006 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC08-01-8
[2]
|
Belantamab |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
B19 |
Mc-Val-Cit-PABC |
|
|
WO2024169913A1 ADC08-01-4
[2]
|
Belantamab |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
B19 |
Mc-Val-Cit-PABC |
|
|
WO2024222841A1 ADC38
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC38-4
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC39
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(S)B19 |
OXD-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC40
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(S)B19 |
OXDc-VA-PAB (Glu) |
|
|
WO2024222841A1 ADC41
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(S)B19 |
OXD-VA-PAB (Glu) |
|
|
WO2024222841A1 ADC42
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC43
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(R)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC44
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B61 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC45
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B63 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC55
[3]
|
018 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC56
[3]
|
019 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC57
[3]
|
020 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC58
[3]
|
021 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC59
[3]
|
022 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC60
[3]
|
023 (CD123) |
Interleukin-3 receptor subunit alpha (IL3RA) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC62-4
[3]
|
008 (BCMA) |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC62
[3]
|
008 (BCMA) |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC64-4
[3]
|
008 (BCMA) |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
(S)B19 |
Undisclosed |
|
|
WO2024222841A1 ADC64
[3]
|
008 (BCMA) |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
(S)B19 |
Undisclosed |
|
|
WO2024222841A1 ADC65
[3]
|
019 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
B63 |
Mc-Val-Ala-PABC |
|
|
WO2024222841A1 ADC66
[3]
|
022 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
B63 |
Mc-Val-Ala-PABC |
|
|
WO2024222841A1 ADC67
[3]
|
023 (CD123) |
Interleukin-3 receptor subunit alpha (IL3RA) |
(S)B19 |
Mc-Val-Ala-PABC |
|
|
T-ADC-2
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
T-ADC
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(S)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC39-4
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(S)B19 |
OXD-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC40-4
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(S)B19 |
OXDc-VA-PAB (Glu) |
|
|
WO2024222841A1 ADC41-4
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(S)B19 |
OXD-VA-PAB (Glu) |
|
|
WO2024222841A1 ADC42-4
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC43-4
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
(R)B19 |
OXDc-VA-PAB (PEG) |
|
|
WO2024222841A1 ADC44-4
[3]
|
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (HER2) |
B61 |
OXDc-VA-PAB (PEG) |
References